Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings Inc (RVPH) focuses on developing novel therapies for central nervous system disorders and cardiometabolic diseases through its proprietary drug discovery platform. This page provides investors and industry observers with timely updates on clinical developments, regulatory milestones, and corporate announcements.
Access comprehensive coverage of Reviva's progress including clinical trial results, regulatory submissions, and strategic partnerships. Our curated news collection enables efficient tracking of the company's lead candidates like Brilaroxazine (RP5063) and RP1208 through critical development phases.
Key updates include progress in neuropsychiatric drug development, intellectual property advancements, and financial reporting. The resource serves investors requiring detailed insights into therapeutic pipeline maturation and market positioning within competitive CNS/pharma sectors.
Bookmark this page for streamlined access to Reviva's latest developments. Check regularly for authoritative reporting on clinical data releases, FDA communications, and research collaborations that shape the company's trajectory in biopharmaceutical innovation.
Reviva Pharmaceuticals (NASDAQ: RVPH) reported Q3 2025 results and recent program milestones on November 13, 2025. Key clinical and corporate updates include a planned pre-NDA meeting with FDA in Q4 2025 and a targeted NDA submission in Q2 2026 for brilaroxazine in schizophrenia. The company reported positive 1-year open-label extension (OLE) data (N=446) showing sustained PANSS and functional improvements and generally favorable safety findings.
Other highlights: European patent granted for brilaroxazine in pulmonary fibrosis, completed a public equity offering raising $9.0 million gross, reported a Q3 net loss of $4.0 million, and held $13.2 million cash as of September 30, 2025.
Reviva Pharmaceuticals (NASDAQ: RVPH) will present new data on the anti-inflammatory effects of brilaroxazine at Neuroscience 2025 in San Diego.
The late-breaker poster (Session A.10, LBP010) on Nov 15, 2025, 1:00–5:00 PM PT covers RECOVER Phase 3 double-blind results in acute schizophrenia and 12-month open-label extension data in clinically stable patients, focusing on BDNF and inflammatory cytokines. Abstracts and poster details are available on the Neuroscience 2025 website.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced that European Patent 3749324 was granted by the EPO on Nov 10, 2025, covering use of brilaroxazine to treat pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF).
The patent adds to existing protection in key markets including the United States, China, and Japan. Brilaroxazine is described as having a novel mechanism that targets disrupted serotonin signaling implicated in pulmonary fibrosis. The drug has received Orphan Drug Designation from the U.S. FDA for IPF. Management said the asset is late-stage and has been well-tolerated across large patient populations, supporting plans to expand clinical development from schizophrenia into additional indications.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO, will participate in the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025 in New York City.
The conference will feature more than 60 selected companies, over 500 institutional and high-net-worth investors, main-stage presentations, expert panels, curated one-on-one meetings, and networking sessions designed to connect growth companies with the investment community.
Investors seeking registration or agenda details are directed to the Spartan Capital Investor Conference 2025 registration page.
Reviva (NASDAQ: RVPH) will present data on negative symptoms for brilaroxazine from the Phase 3 RECOVER program at CNS Summit 2025 in Boston.
The presentation covers results from the double‑blind RECOVER trial in acute exacerbation of schizophrenia and the long‑term open‑label extension in clinically stable patients over one year. Poster Number 32 is scheduled for Nov 3 and Nov 4, 2025, 5:00–7:00 PM ET. The conference runs Nov 2–5, 2025. Abstracts and additional details are available on the CNS Summit 2025 website.
Reviva Pharmaceuticals (NASDAQ: RVPH) said CEO Laxminarayan Bhat, PhD, will join a Key Opinion Leader webinar and fireside chat hosted by A.G.P./Alliance Global Partners on October 10, 2025 at 11:00 AM ET.
The session will include KOLs Dr. Larry Ereshefsky and Dr. Mark Opler, focus on the unmet need and treatment landscape for schizophrenia, and discuss phase 3 clinical data for Reviva’s lead candidate brilaroxazine. The conversation will be moderated by James Molloy of A.G.P. A replay will be posted in Reviva’s investor relations section after the event.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, announced its participation in the 4th Annual Roth Healthcare Opportunities Conference on October 9, 2025, in New York.
CEO Laxminarayan Bhat will join a panel discussion titled "Small Firms Tackling Blockbuster Indications" at 8:00 AM ET and will be available for one-on-one meetings with investors throughout the day.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate presentation on Tuesday, September 30, 2025, at 10:15 AM ET.
The virtual event will include a corporate presentation and one-on-one meetings with management. Investors interested in scheduling meetings can contact Lytham Partners directly or register through the conference website.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced the pricing of a $9 million public offering. The offering includes 27 million shares of common stock (or equivalents) along with Series E and F warrants, priced at $0.335 per share and accompanying warrants.
The Series E warrants will expire in 5 years while Series F warrants will expire in 12 months, both with an exercise price of $0.335 per share. The offering is expected to close around September 22, 2025. Proceeds will support research and development activities and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a proposed public offering of common stock and warrants. The offering will include shares of common stock (or equivalents) and warrants to purchase common stock, with A.G.P./Alliance Global Partners serving as the sole placement agent.
The proceeds will be used to fund research and development activities and for working capital purposes. The securities will be offered through an effective shelf registration statement on Form S-3. The completion of the offering is subject to market conditions, with no guaranteed size or terms.
FAQ
What is the current stock price of Reviva Pharmaceutcls Hldgs (RVPH)?
What is the market cap of Reviva Pharmaceutcls Hldgs (RVPH)?
